Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ocugen, Inc.

Equities

OCGN

US67577C1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
1.78 USD +3.49% Intraday chart for Ocugen, Inc. -10.10% +209.57%
May. 15 Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study MT
May. 15 Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
PR
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
PR
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors
BU
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors
BU
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
GL
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
PR
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
PR
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study
MT
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
GL
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy
CI
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
PR
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
NE
Transcript : Ocugen, Inc., Q1 2024 Earnings Call, May 14, 2024
Ocugen Provides Business Update with First Quarter 2024 Financial Results
GL
Ocugen: Q1 Earnings Snapshot
AQ
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
OCUGEN TO PRESENT AT MAY 2024 INVESTOR CONFERENCES
AQ
OCUGEN ANNOUNCES DISTRIBUTION OF SERIES C PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK
AQ
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. News Ocugen, Inc.